Sanofi considering up to 1,680 job cuts in Europe

Reading Time: 2 minutes

Sanofi is considering cutting up to 1,680 jobs in Europe, two sources familiar with the matter said on Friday, as the French drugmaker outlined plans to reduce costs to staff representatives.

One source said the job measures would be carried out over three years. The sources declined to be identified because the plan has not been announced. Sanofi officials had no immediate comment.

Reuters reported on Thursday that Sanofi was considering cutting hundreds of jobs and would discuss potential steps with staff representatives over the coming days.

The reorganisation could involve several European countries and possibly others outside the region, as well as all the divisions of Sanofi except the vaccines and rare diseases unit Genzyme, the sources said.

Three sources said around 1,000 jobs in France were at risk. One of the sources said the cuts would take place over a three-year period, with no forced redundancies.

Sanofi said strategy matters would be discussed at two meetings convened for June 26-29. “Information will be shared with staff representatives first and no redundancy plan will be presented then,” the company said in an e-mailed statement.

The discussions come after Hudson announced in December plans to cut 2 billion euros ($2.24 billion) in costs by 2022. He joined the company in September from Novartis.

“The COVID-19 (pandemic) had slowed the announcement, but (the measures) are part of the CEO roadmap,” one of the sources said.

Hudson has pledged to commit resources in areas where he believes Sanofi can secure leading positions.

Since his arrival, the company ended research in diabetes and cardiovascular, an area where Sanofi had lost ground over the years, narrowed the number of its divisions and set out higher profit targets.

The group has also been bulking up, including in the lucrative field of cancer drugs. It announced a deal last year to buy U.S. biotechnology firm Synthorx for about $2.5 billion.

Vaccines are also a top priority and the company is currently working on two candidates to prevent COVID-19, the illness caused by the new coronavirus that has killed more than 483,000 globally, one in partnership with GlaxoSmithKline and another with U.S. Translate Bio.

Sanofi said on June 16 it would invest 610 million euros at two French sites to turn them into a hub dedicated to research, development and production of vaccines, with some 200 new jobs expected to be created on one of the locations.

Via Reuters

Once you're here...

%d bloggers like this: